Open AccessImpact of ADCY9 Genotype on Response to Anacetrapib
Author(s) -
Jemma C. Hopewell,
M Ibrahim,
Michael Hill,
Peter M. Shaw,
Eugene Braunwald,
Robert O. Blaustein,
Louise Bowman,
Martin J Landray,
Marc S. Sabatine,
Rory Collins,
Hps
Publication year - 2019
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.119.041546
Subject(s) - medicine , cholesterylester transfer protein , placebo , myocardial infarction , randomized controlled trial , vascular disease , stroke (engine) , hazard ratio , cholesterol , lipoprotein , confidence interval , pathology , mechanical engineering , alternative medicine , engineering
Exploratory analyses of previous randomized trials generated a hypothesis that the clinical response to cholesteryl ester transfer protein (CETP) inhibitor therapy differs by ADCY9 genotype, prompting the ongoing dal-GenE trial in individuals with a particular genetic profile. The randomized placebo-controlled REVEAL trial (Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification) demonstrated the clinical efficacy of the CETP inhibitor anacetrapib among patients with preexisting atherosclerotic vascular disease. In the present study, we examined the impact of ADCY9 genotype on response to anacetrapib in the REVEAL trial.